Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.
作者信息
Gupta Shruti, Strohbehn Ian A, Wang Qiyu, Hanna Paul E, Seethapathy Rituvanthikaa, Prosek Jason M, Herrmann Sandra M, Abudayyeh Ala, Malik A Bilal, Loew Sebastian, Carlos Christopher A, Chang Wei-Ting, Beckerman Pazit, Mithani Zain, Shah Chintan V, Renaghan Amanda D, de Seigneux Sophie, Campedel Luca, Kitchlu Abhijat, Shin Daniel Sanghoon, Coppock Gaia, Lumlertgul Nuttha, Garcia Pablo, Ortiz-Melo David I, Rashidi Arash, Sprangers Ben, Aggarwal Vikram, Benesova Karolina, Jhaveri Kenar D, Cortazar Frank B, Weins Astrid, Zuo Yiqin, Mooradian Meghan J, Reynolds Kerry L, Leaf David E, Sise Meghan E
机构信息
Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
Kidney Int. 2022 Oct;102(4):930-935. doi: 10.1016/j.kint.2022.07.019. Epub 2022 Aug 11.
Abstract
摘要
相似文献
1
Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.接受派姆单抗联合治疗与派姆单抗单药治疗的晚期肺癌患者的急性肾损伤
Kidney Int. 2022 Oct;102(4):930-935. doi: 10.1016/j.kint.2022.07.019. Epub 2022 Aug 11.
2
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
3
A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer.帕博利珠单抗联合化疗对比帕博利珠单抗单药治疗晚期或复发性非小细胞肺癌的回顾性分析。
Thorac Cancer. 2021 May;12(9):1387-1397. doi: 10.1111/1759-7714.13915. Epub 2021 Mar 12.
4
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.帕博利珠单抗联合多西他赛对比多西他赛单药用于既往治疗的晚期非小细胞肺癌患者的疗效和安全性：PROLUNG 期 2 随机临床试验。
JAMA Oncol. 2020 Jun 1;6(6):856-864. doi: 10.1001/jamaoncol.2020.0409.
5
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.帕博利珠单抗单药治疗与帕博利珠单抗联合化疗治疗非小细胞肺癌患者的多中心回顾性试验。
Thorac Cancer. 2022 Jan;13(2):228-235. doi: 10.1111/1759-7714.14252. Epub 2021 Dec 5.
6
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
7
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
8
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.KEYNOTE-021 队列 G：培美曲塞和卡铂联合或不联合帕博利珠单抗作为一线治疗晚期非鳞状非小细胞肺癌的 24 个月总生存数据。
J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21.
9
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.卡铂和培美曲塞联合或不联合帕博利珠单抗用于晚期非鳞状非小细胞肺癌：开放标签KEYNOTE-021研究的随机2期队列研究
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
10
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.在程序性死亡受体配体1（PD-L1）表达≥50%的非小细胞肺癌患者中，一线使用帕博利珠单抗联合或不联合铂类双药化疗。
Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.
引用本文的文献
1
The differentiation and intervention strategies for acute kidney injury after or induced by immune checkpoint inhibitors.免疫检查点抑制剂治疗后或所致急性肾损伤的鉴别与干预策略
Am J Cancer Res. 2025 Apr 15;15(4):1480-1493. doi: 10.62347/JECH8448. eCollection 2025.
2
Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review.抗PD1和p53免疫组化评估肾活检以解决铂类和帕博利珠单抗诱导的急性肾损伤之间的困境：病例报告与综述
J Clin Med. 2024 Mar 22;13(7):1828. doi: 10.3390/jcm13071828.
3
Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.免疫检查点抑制剂治疗的癌症患者发生急性肾损伤的发生率和风险因素：系统评价和荟萃分析。
Front Immunol. 2023 May 29;14:1173952. doi: 10.3389/fimmu.2023.1173952. eCollection 2023.
4
Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events.肿瘤学与肾脏领域的免疫疗法：肾脏免疫相关不良事件评估与管理的临床综述
Clin Kidney J. 2023 Jan 28;16(6):939-951. doi: 10.1093/ckj/sfad014. eCollection 2023 Jun.
5
Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review.免疫检查点抑制剂相关肾损伤的临床病理特征：一项系统评价
J Clin Med. 2023 Feb 8;12(4):1349. doi: 10.3390/jcm12041349.
6
Onconephrology 2022: An Update.《Onconephrology 2022：更新》。
Kidney360. 2023 Feb 1;4(2):258-271. doi: 10.34067/KID.0001582022. Epub 2022 Dec 9.
本文引用的文献
1
Acute kidney injury in patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗患者的急性肾损伤。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003467.
2
Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.接受免疫检查点抑制剂治疗的患者发生肾脏不良事件的比较风险：一项贝叶斯网络荟萃分析
Front Oncol. 2021 Jun 16;11:662731. doi: 10.3389/fonc.2021.662731. eCollection 2021.
3
Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC.培美曲塞和帕博利珠单抗联合治疗在转移性非鳞状非小细胞肺癌患者中的肾毒性。
J Thorac Oncol. 2020 Sep;15(9):1472-1483. doi: 10.1016/j.jtho.2020.04.021. Epub 2020 Apr 30.
4
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.免疫检查点抑制剂相关 AKI 的临床特征和结局：一项多中心研究。
J Am Soc Nephrol. 2020 Feb;31(2):435-446. doi: 10.1681/ASN.2019070676. Epub 2020 Jan 2.
5
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.培美曲塞维持治疗晚期非小细胞肺癌患者的肾功能损害：一项队列研究。
Eur Respir J. 2018 Oct 25;52(4). doi: 10.1183/13993003.00884-2018. Print 2018 Oct.
6
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
7
Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.顺铂治疗第一疗程后急性肾损伤风险预测模型的建立与验证。
J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161. Epub 2018 Jan 10.
8
Kidney tubular toxicity of maintenance pemetrexed therapy.维持性培美曲塞治疗的肾小管毒性。
Am J Kidney Dis. 2011 Nov;58(5):817-20. doi: 10.1053/j.ajkd.2011.04.030. Epub 2011 Aug 17.
9
A new equation to estimate glomerular filtration rate.一种估算肾小球滤过率的新公式。
Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
Zotero 插件